DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Zinman B, Bhosekar V, Busch R. et al.
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
Lancet Diabetes Endocrinol 2019;
7 (05) 356-367
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.